Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04343755
Recruitment Status : Recruiting
First Posted : April 13, 2020
Last Update Posted : July 16, 2020
Sponsor:
Information provided by (Responsible Party):
Hackensack Meridian Health

Brief Summary:
  • This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
  • Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first.
  • Interim analysis will be permitted as described in the statistical section 8.
  • The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: Convalescent Plasma Phase 2

Detailed Description:

Overall study design

  • This is a single arm phase IIa study of convalescent plasma for the treatment of individuals hospitalized with COVID-19 infection.
  • Subjects will be considered as having completed the study after 60 (+/- 3) days, unless consent withdrawal or death occurs first.
  • Interim analysis will be permitted as described in the statistical section 8.
  • The final analysis will be conducted once the last subject completes the day 60 visit or withdraws from the study.

Number of subjects

• Up to 36 patients in track 2, and 19 patients in track 3 as described in the statistical section 8.

Overall study duration

  • The study begins when the first subject (this will likely be a donor) signs the informed consent. The study will end once the last enrolled subject completes the study (likely a recipient).
  • The expected duration of the study is approximately 12 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 55 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection
Actual Study Start Date : April 9, 2020
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : April 2021

Arm Intervention/treatment
Experimental: Convalescent Plasma
Fresh or frozen plasma will be infused one time to patients
Biological: Convalescent Plasma
Fresh or frozen plasma will be infused one time to hospitalized patients with COVID-19 infection




Primary Outcome Measures :
  1. For patients hospitalized for COVID-19 but not intubated [ Time Frame: 7 Days ]
    Mechanical ventilation rate at 7 days from starting treatment in hospitalized COVID-19 patients

  2. Primary objective for patients with COVID-19 already intubated [ Time Frame: 30 Days ]
    Mortality rate at 30 days from starting treatment for patients with COVID-19


Secondary Outcome Measures :
  1. Duration of hospitalization [ Time Frame: 60 Days ]
    The duration of hospitalization is defined as the time in days from the first day of hospitalized to the date of discharge or death. Patients who are not discharged, are alive and still in the hospital on the date of closing follow-up, or lost follow-up on the date of closing follow-up will be considered censored on that date.

  2. Duration of mechanical ventilation [ Time Frame: 60 Days ]
    The duration of mechanical ventilation is defined as the time in days from the first day of using mechanical ventilation to the last day of using mechanical ventilation. All evaluable patients will be included and no censoring for this analysis.

  3. Time to symptoms resolution [ Time Frame: 60 Days ]
    The time to symptom resolution is defined as the time in days from new therapy initiation to the first documented symptom resolution as assessed by local site. Patients whose symptom are not resolved, who are dead, or lost follow-up on the designed follow-up date will be censored on that date.

  4. Overall survival [ Time Frame: 60 Days ]
    Overall survival will be defined as the time in days from study entry to death. Patients who are alive on the date of closing follow-up will be censored on that date.

  5. Rate of virologic clearance by nasopharyngeal swab at day 10 [ Time Frame: 60 Days ]
  6. Impact of donor titers level on efficacy [ Time Frame: 60 Days ]
  7. Impact of donor titers level on safety [ Time Frame: 60 Days ]
  8. Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60 [ Time Frame: 0, 3, 10, 30, and 60 Days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Donor Eligibility Criteria:

  • Age 18-60
  • A history of a positive nasopharyngeal swab for COVID-19 or a history of positive titer test.
  • At least 14 days from resolution of COVID-19-associated symptoms including fevers
  • One negative nasopharyngeal swabs for COVID-19 RNA
  • Covid-19 neutralizing antibody >1:64
  • Adequate venous access for apheresis
  • Meets donor eligibility criteria in accordance to Hackensack University Medical Center (HUMC) Collection Facility at the John Theurer Cancer Center (JTCC) if collecting at the JTCC, and all regulatory agencies as describes in SOP 800 01 (Appendix A)
  • Required testing of the donor and product must be performed in accordance to FDA regulations (21 CFR 610.40), and the donation must be found suitable (21 CFR 630.30)

Recipient Eligibility Criteria:

Recipients age >18 years old, are assigned to one of two clinical tracks, track 2 or 3, based on COVID-19 disease severity. Onset of first symptoms < 9 days.

Track 2:

  • Hospitalized, moderate symptoms requiring medical care for COVID-19 infection
  • Symptoms may include fever, dyspnea, dehydration among others
  • Hypoxemia may be present but is not a requirement

Track 3:

  • Requiring mechanical ventilation for the care of COVID-19 infection
  • Requiring non-invasive positive pressure ventilation (NIPPV), such as continuous airway pressure (CPAP),bi-level positive airway pressure (BiPAP) or high flow nasal canula (HFNC).

Recipient exclusion criteria:

  • History of severe transfusion reaction to plasma products
  • Infusion of immune globulin within the previous 30 days
  • AST or ALT > 10 x upper limit of normal
  • Requirement for vasopressors
  • COVID-19-associated acute kidney injury requiring dialysis
  • DNR status

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04343755


Contacts
Layout table for location contacts
Contact: Mariefel Vendivil 551-996-5828 Mariefel.Vendivil@HackensackMeridian.org
Contact: Marlo Kemp 551-996-4464 Marlo.Kemp@HackensackMeridian.org

Locations
Layout table for location information
United States, New Jersey
Hackensack University Medical Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Mariefel Vendivil    551-996-5828    Mariefel.Vendivil@HackensackMeridian.org   
Contact: Marlo Kemp    551-996-4464    Marlo.Kemp@HackensackMeridian.org   
Principal Investigator: Michele L Donato, MD         
Sponsors and Collaborators
Hackensack Meridian Health
Investigators
Layout table for investigator information
Principal Investigator: Michele L Donato, MD Hackensack Meridian Health
Publications:

Layout table for additonal information
Responsible Party: Hackensack Meridian Health
ClinicalTrials.gov Identifier: NCT04343755    
Other Study ID Numbers: Pro2020-0375
First Posted: April 13, 2020    Key Record Dates
Last Update Posted: July 16, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hackensack Meridian Health:
Coronavirus
Covid19
SARS-CoV-2
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection